Iron and infection: Competition between host and microbes for a precious element

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 2, 2002, Pages 411-426

  Marx, J J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

HIV; Immune system; Infection; Iron; Iron chelators; Macrophages; Malaria

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BLEOMYCIN; CYTOSTATIC AGENT; DEFERIPRONE; DEFEROXAMINE MESYLATE; ENTEROCHELIN; ERYTHROPOIETIN; FERRICHROME; FERRIOXAMINE; HEMOGLOBIN; HEMOPEXIN; INDINAVIR; IRON; IRON CHELATING AGENT; LACTOFERRIN; NITROFURANTOIN; PRIMAQUINE; RECOMBINANT ERYTHROPOIETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RITONAVIR; SIDEROPHORE; SULFAMETHOXAZOLE; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNINDEXED DRUG; VACCINE; VARIANT SURFACE GLYCOPROTEIN; VIRULENCE FACTOR; ZIDOVUDINE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HEME; INTERLEUKIN 2; INTERLEUKIN 6; LYMPHOTOXIN; TRANSFERRIN BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGRANULOCYTOSIS; ANEMIA; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIOSTASIS; CHILD; CONTROLLED STUDY; DRUG COST; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; INFANT; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; MICROBIAL METABOLISM; MICROORGANISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; VIRUS INFECTION; ANTIMICROBIAL ACTIVITY; BACTERIAL METABOLISM; BARTONELLA; BONE MARROW; CANDIDA ALBICANS; CHELATION THERAPY; CRYPTOCOCCUS NEOFORMANS; ERYTHROCYTE; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; HEMOCHROMATOSIS; INFECTION; INFLAMMATION; IRON ABSORPTION; IRON BLOOD LEVEL; IRON CHELATION; IRON DEFICIENCY ANEMIA; IRON STORAGE; LISTERIA MONOCYTOGENES; LIVER CELL; MACROPHAGE; MEMBRANE TRANSPORT; MICROBIAL GROWTH; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; PATHOGENICITY; PHAGOCYTE; PLASMODIUM; PLASMODIUM FALCIPARUM; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; SHIGELLA DYSENTERIAE; TH1 CELL; TH2 CELL; TRYPANOSOMA BRUCEI; VIBRIO CHOLERAE; YERSINIA ENTEROCOLITICA; YERSINIA PESTIS; CHEMICALLY INDUCED DISORDER; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANEMIA; BIOLOGICAL TRANSPORT; HUMANS; INFECTION; IRON; IRON CHELATING AGENTS;

EID: 0036428803     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(02)90001-0     Document Type: Review

References (76)

1. Vargas M, Kashefi K, Blunt-Harris EL & Lovley DR. Microbiological evidence for Fe(III) reduction on early Earth. Nature 1998; 395: 65-67.
2. Bullen JJ. The significance of iron in infection. Review of Infectious Diseases 1981; 3: 1127-1138.
3. Crichton RR (ed.) Inorganic Biochemistry of Iron Metabolism. Chichester: John Wiley & Sons Ltd, 2001.
4. de Valk B, Addicks MA, Gosriwatana I et al Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. European Journal of Clinical Investigation 2000; 30: 248-251.
5. Moura E, Noordermeer MA, Verhoeven N et al. Iron release from human monocytes after erythrophagocytosis in vitro: an investigation in normal subjects and hereditary hemochromatosis patients. Blood 1998; 92: 2511-2519.
6. Cornelissen CN & Sparling PF. Iron piracy: acquisition of transferrin-bound iron by bacterial pathogens. Molecular Microbiology 1994; 14: 843-850.
7. Gray-Owen SD & Schryvers AB. Bacterial transferrin and lactoferrin receptors. Trends in Microbiology 1996; 4: 185-191.
8. Bitter W, Gerrits H, Kieft R & Borst P. The role of transferrin-receptor variation in the host range of Trypanosoma brucei. Nature 1998; 391: 499-502.
9. Boelaert J. Iron and Infection. In Crichton RR (ed.) Inorganic Biochemistry of Iron Metabolism, pp 260-284. Chichester: John Wiley & Sons, Ltd, 2001.
10. Baumler A, Koebnik R, Stojiljkovic I et al. Survey on newly characterized iron uptake systems of Yersinia enterocolitica. Zentralblatt für Bakteriologie 1993; 278: 416-424.
11. Henderson DP & Payne SM. Vibrio cholerae iron transport systems: roles of heme and siderophore iron transport in virulence and identification of a gene associated with multiple iron transport systems. Infection and Immunity 1994; 62: 5120-5125.
12. Mey AR & Payne SM. Haem utilization in Vibrio cholerae involves multiple TonB-dependent haem receptors. Molecular Microbiology 2001; 42: 835-849.
13. Stojiljkovic I & Hantke K. Hemin uptake system of Yersinia enterocolitica: similarities with other TonB-dependent systems in gram-negative bacteria. EMBO Journal 1992; 11: 4359-4367.
14. Stojiljkovic I, Larson J, Hwa V et al. HmbR outer membrane receptors of pathogenic Neisseria spp.: iron-regulated, hemoglobin-binding proteins with a high level of primary structure conservation. Journal of Bacteriology 1996; 178: 4670-4678.
15. Eaton JW, Brandt P, Mahoney JR & Lee JT Jr. Haptoglobin: a natural bacteriostat. Science 1982; 215: 691-693.
16. Cope LD, Thomas SE, Latimer JL et al. The 100 kDa haem:haemopexin-binding protein of Haemophilus influenzae: structure and localization. Molecular Microbiology 1994; 13: 863-873.
17. Lewis LA, Gray E, Wang YP et al. Molecular characterization of hpuAB, the haemoglobin-haptoglobin-utilization operon of Neisseria meningitides. Molecular Microbiology 1997; 23: 737-749.
18. Manns JM, Mosser DM & Buckley HR. Production of a hemolytic factor by Candida albicans. Infection and Immunity 1994; 62: 5154-5156.
19. Mabeza GF, Loyevsky M, Gordeuk VR & Weiss G. Iron chelation therapy for malaria: a review. Pharmacological Therapy 1999; 81: 53-75.
20. Braun V & Hantke K. Microbial iron uptake. In Crichton RR (ed.) Inorganic Biochemistry of Iron Metabolism, pp 49-82. Chichester: John Wiley & Sons, Ltd, 2001.
21. Touati D. Iron and oxidative stress in bacteria. Archives of Biochemistry and Biophysics 2000; 373: 1-6.
22. Koebnik R, Locher KP & Van Gelder P. Structure and function of bacterial outer membrane proteins: barrels in a nutshell. Molecular Microbiology 2000; 37: 239-253.
23. Braun V. Energy-coupled transport and signal transduction through the gram-negative outer membrane via TonB-ExbB-ExbD-dependent receptor proteins. FEMS Microbiology Reviews 1995; 16: 295-307.
24. Buchanan SK, Smith BS, Venkatramani L et al. Crystal structure of the outer membrane active transporter FepA from Escherichia coli. Nature Structural Biology 1999; 6: 56-63.
25. Askwith C & Kaplan J. Iron and copper transport in yeast and its relevance to human disease. Trends in Biochemical Science 1998; 23: 135-138.
26. Weiss G. Iron and immunity: a double-edged sword. European Journal of Clinical Investigation 2002; 32 (supplement 1): 70-78.
27. De Sousa M, Reimao R, Porto G et al. Iron and lymphocytes: reciprocal regulatory interactions. Current Studies in Hematology and Blood Transfusion 1991; 58: 171-177.
28. Porto G, Reimao R, Goncalves C et al. Haemochromatosis as a window into the study of the immunological system: a novel correlation between CD8+ lymphocytes and iron overload. European Journal of Haematology 1994; 52: 283-290.
29. Thorson JA, Smith KM, Gomez F et al. Role of iron in T cell activation: TH1 clones differ from TH2 clones in their sensitivity to inhibition of DNA synthesis caused by IgG Mabs against the transferrin receptor and the iron chelator deferoxamine. Cell Immunology 1991; 134: 126-137.
30. Leusen JHW, Verhoeven AJ & Roos D. Interactions between the components of the human NADPH oxidase: a review about the intrigues in the phox family. Frontiers of Bioscience 1996; 1: d72-d9O.
31. Thrasher AJ, Keep NH, Wientjes F & Segal AW. Chronic granulomatous disease. Biochimica Biophysica Acta 1994; 1227: 1-24.
32. Hoepelman IM, Bezemer WA, Vandenbroucke-Grauls CM et al, Bacterial iron enhances oxygen radical-mediated killing of Staphylococcus aureus by phagocytes. Infection and Immunity 1990; 58: 26-31.
33. Hoepelman IM, Jaarsma EY, Verhoef J & Marx JJM. Polynuclear iron complexes impair the function of polymorphonuclear granulocytes. British Journal of Haematology 1988; 68: 385-389.
34. Hoepelman IM, Bezemer WA, van Doornmalen E et al. Lipid peroxidation of human granulocytes (PMN) and monocytes by iron complexes. British Journal of Haematology 1989; 72: 584-588.
35. Vidal SM, Malo D, Vogan K et al. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell 1993; 73: 469-485.
36. Bellamy R. The natural resistance-associated macrophage protein and susceptibility to intracellular pathogens. Microbes and Infection 1999; 1: 23-27.
37. Lee GR. The anemia of chronic disease. Seminars in Hematology 1983; 20: 61-80.
38. Spivak JL. The blood in systemic disorders. Lancet 2000; 355: 1707-1712.
39. van Iperen CE, van de Wiel A & Marx JJM. Acute event-related anaemia. British Journal of Haematology 2001; 115: 739-743.
40. van Iperen CE, van de Wiel A, de Bruin M & Marx JJM. Total hip replacement surgery does not influence RBC survival. Transfusion 2000; 40: 1235-1238.
41. Biesma DH, van de Wiel A, Beguin Y et al. Post-operative erythropoiesis is limited by the inflammatory effect of surgery on iron metabolism. European Journal of Clinical Investigation 1995; 25: 383-389.
42. van Iperen CE, Kraaijenhagen RJ, Biesma DH et al. Iron metabolism and erythropoiesis after surgery. British Journal of Surgery 1998: 85: 41-45.
43. Weinberg ED. Iron loading and disease surveillance. Emerging Infectious Diseases 1999; 5: 346-352.
44. Oppenheimer SJ. Iron and its relation to immunity and infectious disease. Journal of Nutrition 2001; 131: 616S-633S.
45. van Asbeck BS, Verbrugh HA, van Oost BA et al. Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. British Medical Journal 1982; 284: 542-544.
46. Hoen B. Iron and infection: clinical experience. American Journal of Kidney Diseases 1999; 34: S30-S34.
47. Kooistra MP, Kersting S, Gosriwatana I et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. European Journal of Clinical Investigation 2002; 32 (supplement 1): 36-41.
48. Esposito BP, Breuer W, Slotki I & Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. European Journal of Clinical Investigation 2002; 32 (supplement 1): 42-49.
49. Cighetti G, Duca L, Bortone L et al. Oxidative status and malondialdehyde in β-thalassaemia patients. European Journal of Clinical Investigation 2002; 32 (supplement 1): 55-60.
50. Murray MJ, Murray NJ, Murray AB & Murray MB. Refeeding-malaria and hyperferraemia. Lancet 1975; i: 653-654.
51. Higgs JM & Wells RS. Chronic muco-cutaneous candidiasis: new approaches to treatment. British Journal of Dermatology 1973; 89: 179-190.
52. Weijmer MC, Neering H & Welten C. Preliminary report: furunculosis and hypoferraemia. Lancet 1990; 336: 464-466.
53. Hayashi H, Takikawa T, Nishimura N et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. American Journal of Gastroenterology 1994; 89: 986-988.
54. Rigamonti C, Andorno S, Maduli E et al. Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. European Journal of Clinical Investigation 2002; 32 (supplement 1): 28-35.
55. Gordeuk VR, Delanghe JR, Langlois MR & Boelaert JR. Iron status and the outcome of HIV infection: an overview. Journal of Clinical Virology 2001; 20: 111-115.
56. Nabel G & Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326: 711-713.
57. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Annals of the New York Academy of Sciences 1964; 119: 758-768.
58. Kontoghiorghes GJ, Agarwal MB, Grady RW et al. Deferiprone for thalassaemia. Lancet 2000; 356: 428-429.
59. Kontoghiorghes GJ, Pattichi K, Hadjigavriel M & Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (LI). Transfusion Science 2000; 23: 211-223.
60. 3+ values. Transfusion Science 2000; 23: 201-209.
61. Voest EE, Vreugdenhil G & Marx JJM. Iron-chelating agents in non-iron overload conditions. Annals of Internal Medicine 1994; 120: 490-499.
62. Jones RL, Peterson CM, Grady RW et al. Effects of iron chelators and iron overload on Salmonella infection. Nature 1977; 267: 63-65.
63. Windus DW, Stokes TJ, Julian BA & Fenves AZ. Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine. Annals of Internal Medicine 1987; 107: 678-680.
64. Boelaert JR, Fenves AZ & Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. American Journal of Kidney Diseases 1991; 18: 660-667.
65. Abcarian PW & Demas BE. Systemic Yersinia enterocalitica infection associated with iron overload and deferoxamine therapy. American Journal of Roentgenology 1991; 157: 773-775.
66. Ampel NM, Bejarano GC & Saavedra M Jr. Deferoxamine increases the susceptibility of beta-thalassemic, iron-overloaded mice to infection with Listeria monocytogenes. Life Sciences 1992; 50: 1327-1332.
67. van Asbeck BS, Marcelis JH, Marx JJM et al. Inhibition of bacterial multiplication by the iron chelator deferoxamine: potentiating effect of ascorbic acid. European Journal of Clinical Microbiology 1983; 2: 426-431.
68. van Asbeck BS, Marcelis JH, van Kats JH et al. Synergy between the iron chelator deferoxamine and the antimicrobial agents gentamicin, chloramphenicol, cefalothin, cefotiam and cefsulodin. European Journal of Clinical Microbiology 1983; 2: 432-438.
69. Arnold RR, Brewer M & Gauthier JJ. Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms. Infection and Immunity 1980; 28: 893-898.
70. Aguila A, Herrera AG, Morrison D et al. Bacteriostatic activity of human lactoferrin against Staphylococcus aureus is a function of its iron-binding properties and is not influenced by antibiotic resistance. FEMS Immunology and Medical Microbiology 2001; 31: 145-152.
71. Gordeuk V, Thuma P, Brittenham G et al. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. New England Journal of Medicine 1992; 327: 1473-1477.
72. Gordeuk VR, Thuma PE, Brittenham GM et al. Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood 1992; 79: 308-312.
73. Cabantchik ZI, Moody-Haupt S & Gordeuk VR. Iron chelators as anti-infectives; malaria as a paradigm. FEMS Immunology and Medical Microbiology 1999; 26: 289-298.
74. van Asbeck BS, Georgiou NA, van der Bruggen T et al. Anti-HIV effect of iron chelators: different mechanisms involved. Journal of Clinical Virology 2001; 20: 141-147.
75. Georgiou NA, van der Bruggen T, Oudshoorn M et al. Inhibition of human immunodeficiency virus type I replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. Journal of Infectious Diseases 2000; 181: 484-490.
76. Georgiou NA, van der Bruggen T, Jansen CA et al. The chemotherapeutic agent bleomycin in a two-drug combination with zidovudine, ritonavir or indinavir synergistically inhibits HIV Type-I replication in peripheral blood lymphocytes. International Journal of Antimicrobial Agents 2001; 18: 513-518.